Is NCT07187973 recruiting in Augusta, GA?

Yes, NCT07187973 is currently recruiting participants at its Augusta, GA location. This sickle cell disease clinical trial is actively enrolling qualified participants.

How do I join the sickle cell disease clinical trial in Augusta?

To join this clinical trial in Augusta, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Augusta clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Sickle Cell Disease Clinical Trial in Augusta, GA

Who Can Participate

Inclusion Criteria

Aged 18 years or older at the time of signing the informed consent form (ICF).

Male or female study participants with SCD HbSC or HbSS.

Participants who have been diagnosed with any of the following SCD-related complications: between 1-10 episodes of VOC in the past 12 months, any history of sickle cell related retinopathy, silent cerebral infarct, avascular necrosis, sensorineural hearing loss; or at least 1 episode of priapism, hepatic sequestration, splenic sequestration, or splenic infarct within the last 12 months as assessed locally.

Hgb ≥7.0 g/dL during Screening. The first 2 participants must have an Hgb ≥9 g/dL.

Normal alpha globin gene screen.

Absolute reticulocyte count or % reticulocyte count \>1.5 × upper limit of normal (ULN) during Screening.

TSAT ≥15% at Screening.

Ferritin ≥50 ng/mL for HbSC or ≥100 ng/mL for HbSS (ferritin must be \<1000 ng/mL at Screening).

For participants taking hydroxyurea, L-glutamine, or crizanlizumab, stable dose for at least 2 months prior to Screening and with no anticipated need for dose adjustments during the study.

If male, not vasectomized for at least 6 months, with female sexual partner(s) of childbearing potential, agrees he and partner will use double methods of the following highly effective methods of birth control (described below) from the first dose of randomized study drug until 120 days after the last administration of study drug and must not donate sperm during their study participation:

Stable hormonal contraceptive (≥3 months; female partner) in conjunction with a barrier method (eg, condom \[male or female\] or diaphragm).

Intrauterine device, in place for at least 3 months (female partner) in conjunction with a barrier method (eg, condom \[male or female\] or diaphragm).

Surgically sterile by hysterectomy, bilateral oophorectomy, or bilateral tubal ligation (female partner) in conjunction with a barrier method (eg, condom \[male or female\] or diaphragm).

If female, then EITHER postmenopausal, defined as at least 12 months natural, spontaneous amenorrhea, 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) \>40 mIU/mL at Screening, or at least 6 weeks following surgical menopause (bilateral oophorectomy with or without hysterectomy); surgically sterile, OR agree to use 1 of the following highly effective methods of birth control on Day 1 (or earlier) and for at least 120 days after the last administration of study drug:

Stable hormonal contraceptive (≥3 months) in conjunction with a barrier method (eg, condom \[male or female\] or diaphragm).

Intrauterine device, in place for at least 3 months in conjunction with a barrier method (eg, condom \[male or female\] or diaphragm).

Tubal ligation or single male partner with vasectomy in conjunction with a barrier method (eg, condom \[male or female\] or diaphragm).

Negative pregnancy test (females of childbearing potential) prior to dosing.

Able to understand the study aims, procedures, and requirements, and provide written informed consent.

Able to comply with all study procedures.

Exclusion Criteria

Participants who are receiving regularly scheduled blood (RBC) transfusion therapy or phlebotomy or have received RBC transfusion or phlebotomy within 60 days of Screening.

Hospitalized for VOC or other sickle cell related complication within 14 days of Screening.

Participants with clinically significant bacterial, fungal, parasitic, or viral infection.

Active HIV, hepatitis B, or C. A positive hepatitis or HIV result should be discussed between the Investigator and Sponsor prior to enrollment.

Significant renal dysfunction, evidenced by estimated glomerular filtration rate of \<60 mL/min/1.73 m2 at the Screening visit, as assessed locally.

Hepatic dysfunction characterized by alanine aminotransferase (ALT) \>2.5 × ULN.

Any episode of ACS in the last 6 months.

Prior or planned hematopoietic stem cell transplant or gene therapy.

History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to Screening.

History of invasive malignancies within the last 5 years, except localized cured prostate cancer and cervical cancer, or other malignancies deemed acceptable by the Sponsor.

Major surgery within 8 weeks before Screening or incomplete recovery from any previous surgery.

A history or known allergic reaction to any IP excipients or history of anaphylaxis to any food or drug.

History of alcohol dependence or excessive alcohol consumption, as assessed by the Investigator.

Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at an unacceptable risk or otherwise preclude the participant from participating in the study.

Condition or concomitant medication that would confound the ability to interpret clinical, clinical laboratory, including a major psychiatric condition that has had an exacerbation or required hospitalization in the last 6 months.

If female, pregnant or breastfeeding.

Participation in any other clinical protocol or investigational study that involves administration of experimental therapy and/or therapeutic devices within 30 days of Screening.

Participants with a history of transient ischemic attack or stroke may be considered in consultation with Sponsor.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Augusta?

Yes, this clinical trial (NCT07187973) has an active research site in Augusta, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sickle Cell Disease Treatment Options in Augusta, GA

If you're searching for sickle cell disease treatment options in Augusta, GA, this clinical trial (NCT07187973) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Augusta research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sickle cell disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sickle cell disease clinical trials near you to find additional studies recruiting in your area.

Sickle Cell Disease Clinical Trial in Augusta, GA

Expert Care in Augusta

IRB Approved

No-Cost Care

Apply for This Augusta Location

Why Participate?

Simple Process

About This Sickle Cell Disease Study in Augusta